Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Apollomics Inc. Warrant (APLMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: APLMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.66M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 |
52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20542439 | Price to Sales(TTM) - |
Enterprise Value 20542439 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Apollomics Inc. Warrant
Company Overview
History and Background
Apollomics Inc. Warrant (APLM.WS) is tied to Apollomics Inc., a biopharmaceutical company. Warrants are derivative securities. The warrant gives the holder the right to purchase shares of Apollomics Inc. (APLM) stock at a specified price and date or during a specific period.
Core Business Areas
- Biopharmaceutical Research & Development: Apollomics' primary focus is on the discovery and development of oncology therapies.
Leadership and Structure
Details on Apollomics Inc.'s leadership team can be found in their SEC filings and investor relations materials. The warrant itself doesn't have a leadership team. It's a derivative of the underlying stock, Apollomics Inc.
Top Products and Market Share
Key Offerings
- Pipeline of Oncology Drugs: Apollomics is developing a pipeline of immuno-oncology and targeted therapies. Specific drugs in development and their target markets/competition information are detailed in their investor presentations and SEC filings. Competitors vary depending on the specific drug and its target indication.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with constant innovation in drug development and regulatory changes.
Positioning
Apollomics is positioned as a clinical-stage biopharmaceutical company focused on developing oncology therapies.
Total Addressable Market (TAM)
TAM varies considerably depending on the success of clinical trials and regulatory approvals. APLM's positioning is tied to the potential market of its drug candidates.
Upturn SWOT Analysis
Strengths
- Innovative Pipeline of Drug Candidates
- Strong Focus on Oncology
- Potential for Breakthrough Therapies
Weaknesses
- High Risk of Clinical Trial Failures
- Dependence on Regulatory Approvals
- Limited Revenue Until Product Launch
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion into New Therapeutic Areas
- Accelerated Approval Pathways for Oncology Drugs
Threats
- Competition from Established Pharmaceutical Companies
- Changes in Regulatory Landscape
- Economic Downturn Impacting Healthcare Spending
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- NVS
- AZN
Competitive Landscape
Apollomics Inc. faces intense competition from larger, more established pharmaceutical companies. Its success hinges on securing regulatory approvals and establishing partnerships.
Growth Trajectory and Initiatives
Historical Growth: Track historical growth through the performance of Apollomics (APLM) common stock.
Future Projections: Based on analyst estimates and the potential approval of its drug candidates.
Recent Initiatives: Details about Apollomics Inc.'s recent initiatives would be included in their press releases, investor presentations and SEC filings.
Summary
Apollomics Inc. Warrant value is tied to Apollomics Inc. and its pipeline. Apollomics is a high-risk, high-reward investment due to its clinical-stage status. Success depends on clinical trial outcomes and regulatory approvals. Investors should closely monitor Apollomics' financials and pipeline progress.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings of Apollomics Inc. (APLM)
- Apollomics Inc. Investor Relations
- Financial News Outlets
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investing in warrants and biopharmaceutical companies carries significant risk. Consult with a qualified financial advisor before making any investment decisions. Market share data for Apolloics is an estimate based on the drugs that they have under development and have yet to be approved.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apollomics Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-26 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website |
Full time employees 59 | Website | ||
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.